The TAR-210 study unveils groundbreaking findings in bladder cancer treatment, presenting a promising new approach for ...

Novartis strengthens expands its radioligand therapy arsenal with the acquisition of Mariana Oncology in a $1 billion deal.

The FDA has granted full approval for Tivdak® as a treatment for recurrent or metastatic cervical cancer. It is the first ...

Monteris Medical announced the commercial release of the NeuroBlate NB3 FullFire 1.6mm Laser Probe, the smallest brain ...

GenFleet Therapeutics announced that the US Food and Drug Administration (FDA) has granted clinical trial approval for GFH925 ...

The FDA has approved Novartis' radioligand therapy Lutathera® for pediatric patients with gastroenteropancreatic ...

Xaira Therapeutics, newly launched with over $1 billion in capital, aims to revolutionize drug discovery using artificial ...

Dr. Arutha Kulasinghe, discusses the transformative role of spatial biology in immunotherapy and cancer research in an ...

Flindr Therapeutics has secured €20 million in Series A funding to advance its precision oncology treatments, focusing on a ...

The FDA has approved Anktiva®, a novel immunotherapy for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...

The FDA has approved Pfizer's BEQVEZ, a one-time gene therapy for adults with moderate to severe hemophilia B. This innovative treatment enables patients to produce their own clotting factor IX.

ONCOLife as a cutting-edge oncology magazine designed for oncologists and health professionals. It has flexible format, available both in print and online formats in the US and EU, ONCOLife is ...